P
Peter Radermacher
Researcher at University of Ulm
Publications - 479
Citations - 12086
Peter Radermacher is an academic researcher from University of Ulm. The author has contributed to research in topics: Septic shock & Shock (circulatory). The author has an hindex of 53, co-authored 457 publications receiving 10345 citations. Previous affiliations of Peter Radermacher include Joseph Fourier University.
Papers
More filters
Journal ArticleDOI
High versus Low Blood-Pressure Target in Patients with Septic Shock
Pierre Asfar,Ferhat Meziani,Jean-François Hamel,Fabien Grelon,Bruno Mégarbane,Nadia Anguel,Jean-Paul Mira,Pierre-François Dequin,Soizic Gergaud,Nicolas Weiss,François Legay,Marie Conrad,René Robert,Frédéric Gonzalez,Christophe Guitton,Fabienne Tamion,Jean-Marie Tonnelier,Pierre Guezennec,Thierry Van Der Linden,Antoine Vieillard-Baron,Eric Mariotte,Gael Pradel,Olivier Lesieur,Jean-Damien Ricard,Fabien Hervé,Claude Guérin,Alain Mercat,Jean-Louis Teboul,Peter Radermacher,Abstr Act +29 more
TL;DR: Targeting a mean arterial pressure of 80 to 85 mm Hg, as compared with 65 to 70 mm HG, in patients with septic shock undergoing resuscitation did not result in significant differences in mortality at either 28 or 90 days.
Journal ArticleDOI
Cre-mediated cell ablation contests mast cell contribution in models of antibody- and T cell-mediated autoimmunity
Thorsten B. Feyerabend,Anne Weiser,Annette Tietz,Michael Stassen,Nicola L. Harris,Manfred Kopf,Peter Radermacher,Peter Möller,Christophe Benoist,Diane Mathis,Hans Jörg Fehling,Hans Reimer Rodewald +11 more
TL;DR: Targeted insertion of Cre-recombinase into the mast cell carboxypeptidase A3 locus deleted mast cells in connective and mucosal tissues by a genotoxic Trp53-dependent mechanism.
Journal ArticleDOI
Glucose metabolism and catecholamines.
Eberhard Barth,Gerd Albuszies,Katja Baumgart,Martin Matejovic,Ulrich Wachter,Josef Vogt,Peter Radermacher,Enrico Calzia +7 more
TL;DR: The effects of the various catecholamines on glucose utilization, both under physiologic conditions, as well as during shock states are reviewed, and potential strategies are outlined to influence thecatecholamine-induced effects on glucose homeostasis.
Journal ArticleDOI
Hyperoxia and hypertonic saline in patients with septic shock (HYPERS2S): a two-by-two factorial, multicentre, randomised, clinical trial.
Pierre Asfar,Frédérique Schortgen,Julie Boisramé-Helms,Julien Charpentier,Emmanuel Guerot,Bruno Mégarbane,David Grimaldi,Fabien Grelon,Nadia Anguel,Sigismond Lasocki,Matthieu Henry-Lagarrigue,Frédéric Gonzalez,François Legay,Christophe Guitton,Maleka Schenck,Jean Marc Doise,Jérôme Devaquet,Thierry Van Der Linden,Delphine Chatellier,Jean Philippe Rigaud,Jean Dellamonica,Fabienne Tamion,Ferhat Meziani,Alain Mercat,Didier Dreyfuss,Valérie Seegers,Peter Radermacher +26 more
TL;DR: In patients with septic shock, setting FiO2 to 1·0 to induce arterial hyperoxia might increase the risk of mortality, with a clinically relevant doubling in thehyperoxia group of the number of patients with intensive care unit-acquired weakness.
Journal ArticleDOI
Complement C3 vs C5 inhibition in severe COVID-19: Early clinical findings reveal differential biological efficacy.
Dimitrios C. Mastellos,Bruno Garcia Silva,Benedito Antonio Lopes da Fonseca,NP Fonseca,Maria Auxiliadora-Martins,Sara Mastaglio,Annalisa Ruggeri,Marina Sironi,Peter Radermacher,Akrivi Chrysanthopoulou,Panagiotis Skendros,Konstantinos Ritis,Ilenia Manfra,Simona Iacobelli,Markus Huber-Lang,Bo Nilsson,Despina Yancopoulou,E. Sander Connolly,Cecilia Garlanda,Fabio Ciceri,Antonio M. Risitano,Rodrigo T. Calado,John D. Lambris +22 more
TL;DR: Early clinical results offer important insights into the differential mechanistic basis and underlying biology of C3 and C5 inhibition in COVID-19 and point to a broader pathogenic involvement of C 3-mediated pathways in thromboinflammation.